Lyndsay J . Willmott

Department

Obstetrics & Gynecology (Phoenix)

Position

Assistant Professor

Publications

• International journal of gynecological cancer
  Richardson Debra, etal RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY
  35:11, p. 102612 2025
• International journal of gynecological cancer
  Slomovitz Brian, etal SURVIVAL AND SAFETY OUTCOMES IN PART 1 OF THE ENGOT-EN6-NSGO/GOG-3031/RUBY TRIAL OF DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL IN THE PRESENCE OF COMMON COMORBIDITIES
  35:11, p. 102251 2025
• International journal of gynecological cancer
  Lorusso Domenica, etal SAFETY OF RUCAPARIB MONOTHERAPY IN ADVANCED HIGH-GRADE OVARIAN CANCER CLINICAL TRIALS
  35:11, p. 102262 2025
• Gynecologic oncology
  Herzog Thomas, etal Efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer: An open-label randomized active-controlled phase II clinical study (GOG-3044)
  200, p. 8 2025
• Gynecologic oncology
  Simpkins Fiona, etal Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)
  200, p. 8 - 9 2025
• Gynecologic oncology
  Mirza Mansoor, etal Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
  200, p. 87 2025
• Journal of clinical oncology
  Heitz Florian, etal Time to quality of life (QoL) improvement or deterioration in patients (pts) with primary advanced or recurrent endometrial cancer (pA/R EC) treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
  43:16_suppl, p. 5600 - 5600 2025
• Journal of clinical oncology
  Winer Ira Seth, etal Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study
  43:16_suppl, p. 3039 - 3039 2025
• Gynecologic oncology reports
  Le Ngoc-Anh, etal Outpatient hybrid intracavitary-interstitial brachytherapy for cervical cancer with minimal sedation in a freestanding setting, p. 101767 2025
• Gynecologic oncology
  You Benoit, etal Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
  197, p. 66 2025
• Gynecologic oncology
  Herzog Thomas J, etal An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)
  194, p. 145 - 152 2025
• International journal of gynecological cancer
  Lokich Elizabeth, etal Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial
  35:2, p. 101722 2025
• Therapeutic advances in medical oncology
  Powell Matthew A, etal A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
  17, p. 17588359251342241 2025
• Journal of comparative effectiveness research
  Graybill Whitney S, etal Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
  14:1, p. e240133 2025
• J Comp Eff Res
  Graybill Whitney S, etal Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
  14:1, p. e240133 2025
• Gynecologic oncology
  Graybill Whitney, etal Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
  190, p. S274 - S275 2024
• Gynecologic oncology
  Powell Matthew, etal Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
  190, p. S4 - S5 2024
• J Clin Oncol
  Slomovitz Brian M, etal Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors, p. JCO2401887 2024
• International journal of gynecological cancer
  Lorusso Domenica, etal TP003/#1538  Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy
  34, p. A348 - A348 2024
• Journal of clinical oncology
  Santin Alessandro D, etal Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer, p. JCO2302767 2024
• Journal of clinical oncology
  Lokich Elizabeth, etal Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial
  42:16_suppl, p. 5607 - 5607 2024
• ESMO open
  Haslund C.A., etal 51P Efficacy and safety by time to maintenance therapy treatment initiation in PRIMA/ENGOT-OV26/GOG-3012
  9, p. 103558 2024
• Clinical cancer research
  Lorentzen Georgia M, etal Cervicovaginal metabolome and tumor characteristics for endometrial cancer detection and risk stratification 2024
• Therapeutic advances in medical oncology
  Auranen Annika, etal Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
  16, p. 17588359241277656 - 2024
• Journal of minimally invasive gynecology
  Stewart Chelsea, etal Factors associated with inpatient narcotic medication usage after robotic assisted laparoscopy 2023
• Journal of geriatric oncology
  Moore Madison S., etal Robotic-assisted gynecologic surgery in an older population: A comparison study
  14:6, p. 101533 - 101533 2023
• International journal of gynecological cancer
  Oaknin Ana, etal 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246)
  32:Suppl 2, p. A472 - A472 2022
• Gynecologic oncology
  Chase Dana M., etal Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial
  166:3, p. 494 - 502 2022
• International journal of gynecological cancer
  Chase D M, etal 961 Impact of disease progression on health-related quality of life of advanced ovarian cancer (AOC) patients – pooled analysis from the PRIMA trial
  31:Suppl 3, p. A284 - A284 2021
• Gynecologic oncology
  Eakin C., etal Cervical Cancer Screening in Pregnancy: Identifying Characteristics of Poor Postpartum Follow-up
  156:3, p. e36 - e36 2020
• Gynecologic oncology
  Moreno A., etal Factors Associated with Increased Narcotic Usage after Undergoing Robotic Assisted Laparoscopy
  147:1, p. 203 - 203 2017
• Gynecologic oncology
  Barnes Dominique, etal Patient characteristics associated with obesity in an endometrial cancer patient: first steps towards the design of a weight loss intervention
  147:1, p. 215 - 215 2017
• Gynecologic oncology
  Barnes Dominique, etal Clinic-based Depression Screening in Gynecologic Oncology Patients using the Patient Health Questionnaires-2 (PHQ-2): are we identifying the highest risk patients?
  147:1, p. 215 - 215 2017
• Gynecologic oncology
  Vo E.H., etal Robotic-assisted Gynecologic Surgery in an Elderly Population: A Comparison Study
  147:1, p. 204 - 205 2017
• Journal of clinical oncology
  Love Neil, etal The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mu
  35:8_suppl, p. 241 - 241 2017
• Gynecologic oncology research and practice
  Minion Lindsey E., etal Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study
  3:1, p. 4 - 4 2016
• Journal of gynecologic surgery
  Shields Kristin M., etal Ten-Year Food and Drug Administration Reporting on Robotic Complications in Gynecologic Surgery
  31:6, p. 331 - 335 2015
• Gynecologic oncology
  Shields K.M., etal Factors associated with low educational background in uterine cancer patients
  137, p. 123 - 123 2015
• Gynecologic oncology
  Craig C., etal The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study
  131:1, p. 264 - 264 2013
• Angiogenesis (London)
  Trapp Valerie, etal Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture
  13:4, p. 305 - 315 2010
• Cancer research (Chicago, Ill.)
  Willmott Lyndsay J., etal Abstract 1399: The effect of radiation therapy with adjunctive oxaliplatin versus cisplatin chemotherapy in cervical cancer cell lines
  70:8_Supplement, p. 1399 - 1399 2010
• Gynecologic oncology
  Monk Bradley J., etal Anti-angiogenesis agents in metastatic or recurrent cervical cancer
  116:2, p. 181 - 186 2010
• Journal of the National Comprehensive Cancer Network
  Willmott L. J., etal Biologics in Cervical Cancer Therapy
  8:12, p. 1417 - 1423 2010
• Journal of oncology
  Willmott Lyndsay J., etal Targeted Therapy in Ovarian Cancer
  2010, p. 740472 - 9 2010
• Expert review of anticancer therapy
  Willmott Lyndsay J, etal Cervical cancer therapy: current, future and anti-angiogensis targeted treatment
  9:7, p. 895 - 903 2009